Compare Amgen, Inc. (AMGN) vs Sezzle Inc (SEZL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Sezzle Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Sezzle Inc trades at $174.44 (market cap $6.03B). The key difference: Amgen, Inc. is far larger — about 32.5× Sezzle Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals.
| AMGN | SEZL | |
|---|---|---|
Market Cap | $196.12B | $6.03B |
Sector | Health | Technology |
52-Week High | $388.16 | $183.24 |
52-Week Low | $271.18 | $50.97 |
Enterprise Value | $241.41B | $6.05B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SEZL trades at $179.38, up 1.3% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock exhibits high profitability with a 30.83% net income margin and 91.95% ROE, though valuation multiples like a P/E of 42.78 suggest premium pricing. Recent news highlights product expansion and raised guidance, supporting positive sentiment.
Outlook remains favorable given robust growth and operational leverage, but risks include high valuation sensitivity and regulatory scrutiny. Analyst consensus is bullish with a $149.50 price target, though current price exceeds this, indicating potential near-term consolidation. Investment appeal hinges on sustained execution amid competitive fintech dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
